Trial Profile
A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2021
Price :
$35
*
At a glance
- Drugs Methylnaltrexone bromide (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 31 Mar 2021 Results of post hoc pooled analysis of (study 302, NCT00402038; study 3200K1-4000, NCT00672477; study 3200K1-3356, NCT00529087 and study 3201, NCT01186770) assessing efficacy and safety of methylnaltrexone, including the effectiveness of opioid treatment, in older adults receiving methylnaltrexone for opioid-induced constipation (OIC), published in the Drugs and Aging.
- 03 Jun 2015 The EC approved RELISTOR (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, according to a Valeant Pharmaceuticals International and Progenics Pharmaceuticals media release.
- 27 Apr 2015 The Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of methylnaltrexone bromide subcutaneous injection (RELISTOR) for the treatment of opioid-induced constipation in adults, according to a Valeant Pharmaceuticals International media release.